Share on StockTwits

Epizyme (NASDAQ:EPZM) major shareholder Ryan D. Drant sold 4,061 shares of Epizyme stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $36.54, for a total value of $148,388.94. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

A number of analysts have recently weighed in on EPZM shares. Analysts at HC Wainwright raised their price target on shares of Epizyme from $40.00 to $45.00 in a research note on Wednesday, August 13th. They now have a “buy” rating on the stock. Separately, analysts at Zacks downgraded shares of Epizyme from an “outperform” rating to a “neutral” rating in a research note on Thursday, August 7th. They now have a $36.80 price target on the stock. Finally, analysts at Wainwright initiated coverage on shares of Epizyme in a research note on Tuesday, July 15th. They set a “buy” rating and a $40.00 price target on the stock.

Epizyme (NASDAQ:EPZM) traded down 5.12% during mid-day trading on Monday, hitting $34.81. The stock had a trading volume of 374,281 shares. Epizyme has a one year low of $18.10 and a one year high of $42.71. The stock has a 50-day moving average of $32.14 and a 200-day moving average of $27.20. The company’s market cap is $1.169 billion.

Epizyme (NASDAQ:EPZM) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.40) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.50) by $0.10. The company had revenue of $9.50 million for the quarter, compared to the consensus estimate of $7.59 million. On average, analysts predict that Epizyme will post $-1.63 earnings per share for the current fiscal year.

Epizyme, Inc is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize personalized therapeutics for patients with genetically defined cancers.

Receive News & Ratings for Epizyme Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.